NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the American Depositary Shares of Advanced Health Intelligence Ltd. Advanced Health Intelligence Ltd.’s security was suspended on July 30, 2024 and has not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the ordinary shares and warrants of noco-noco Inc. noco-noco Inc.’s securities were suspended on November 25, 2024 and have not traded on Nasdaq since that time. Nasdaq a ...

MOLINE, Ill., July 02, 2025 (GLOBE NEWSWIRE) -- QCR Holdings, Inc. (NASDAQ: QCRH) (“QCRH” or the “Company”) announced today that its second quarter ended June 30, 2025, financial results will be released after the market closes on Wednesday, July 23, 2025. The Company will host a conference call and webcast the next day, Thursday, July 24, 2025, at 10:00 a.m. Central Time to discuss the results. Shareholders, analysts, and other interested parties are invited to join. Teleconference: Dial-in information fo ...

AUSTIN, Texas, July 02, 2025 (GLOBE NEWSWIRE) -- Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced foods nationwide, today announced the appointment of William B. (Billy) Cyr to its board of directors effective July 1, 2025. Cyr is an accomplished business leader with more than 40 years of experience in the consumer packaged goods space. Since September 2016, Cyr has served as the Chief Executive Officer of Freshpet, Inc., a pet food company whose mission is to ...

4FRONT-1 Phase 3 expected data readout accelerated from H2 2027 to H1 20274FRONT-2 Phase 3 trial initiated ahead of schedule Streamlined late-stage clinical and pre-commercial organization aligns with focused pipeline shift, as announced in January 2025 EMERYVILLE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigm ...

Core Viewpoint - Arbor Realty Trust, Inc. has announced a private offering of $500 million in Senior Notes with a 7.875% interest rate, maturing in 2030, to qualified institutional buyers and non-U.S. persons [1][2] Group 1: Offering Details - The offering consists of $500 million aggregate principal amount of 7.875% Senior Notes due 2030 [1] - The Notes will be senior, unsecured obligations of Arbor Realty SR, Inc. and guaranteed by Arbor Realty Trust, Inc. on a senior, unsecured basis [1] - The expected closing date for the offering is July 9, 2025, pending customary closing conditions [1] Group 2: Use of Proceeds - A portion of the net proceeds will be used to refinance, redeem, or repay Arbor's remaining outstanding 7.50% Convertible Notes due 2025 [2] - Any remaining proceeds will be allocated for general corporate purposes [2] Group 3: Company Overview - Arbor Realty Trust, Inc. is a nationwide real estate investment trust and direct lender, focusing on loan origination and servicing for multifamily, single-family rental portfolios, and other commercial real estate assets [5] - The company manages a multibillion-dollar servicing portfolio and is a leading lender for government-sponsored enterprise products [5] - Arbor is recognized as a Fannie Mae DUS® lender and Freddie Mac Optigo® Seller/Servicer, and is an approved FHA Multifamily Accelerated Processing (MAP) lender [5]

BEIJING, July 02, 2025 (GLOBE NEWSWIRE) -- Julong Holding Limited (“Julong” or the “Company”) (Nasdaq: JLHL), a growth-oriented provider of intelligent integrated solutions, today announced that, in connection with its previously completed initial public offering (the "Offering") of its Class A ordinary shares, the underwriter has exercised its over-allotment option in full to purchase an additional 187,500 Class A ordinary shares at the public offering price from the Company, bringing additional gross proc ...

ATHENS, Greece, July 02, 2025 (GLOBE NEWSWIRE) -- EuroDry Ltd. (NASDAQ: EDRY, the “Company” or “EuroDry”), an owner and operator of drybulk vessels and provider of seaborne transportation for drybulk cargoes, announced today that its Board of Directors has called an annual meeting of the shareholders to be held on July 23, 2025, at 11:30 a.m. at the offices of Seward & Kissel LLP, located at 901 K Street NW, Suite 800, Washington, DC 20001. Shareholders of record at the close of business on June 25, 2025, a ...

Core Viewpoint - Lixte Biotechnology Holdings, Inc. has successfully closed a private placement raising approximately $5.0 million through the sale of shares and warrants, aimed at supporting its cancer drug development efforts [1][3]. Group 1: Private Placement Details - The offering included the sale of 2,382,084 shares of Common Stock (or Pre-Funded Warrants), 3,573,130 shares of Series B Convertible Preferred Stock, and 6,355,214 Common Warrants [2]. - The Pre-Funded Warrants are immediately exercisable at a price of $0.00001, while the Common Warrants have an initial exercise price of $1.00 per share and expire 60 months after the resale registration statement is effective [2]. - The gross proceeds of approximately $5.0 million consist of $4.0 million paid at closing and $1.0 million to be paid upon the effectiveness of the resale registration statement [3]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Company Overview - Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing new cancer therapies, particularly its lead compound LB-100, which has shown promise in enhancing chemotherapy and immunotherapy outcomes [6][7]. - LB-100 is part of a new treatment paradigm in cancer biology known as activation lethality, with ongoing proof-of-concept clinical trials for various cancer types [7].

Core Insights - Emergent BioSolutions is expanding its NARCANDirect online distribution network to include KLOXXADO Nasal Spray 8 mg, enhancing access to opioid overdose response tools starting July 1, 2025 [1][2] - The addition of KLOXXADO Nasal Spray, a higher dose naloxone product, aims to provide more options for emergency responders and communities in addressing opioid emergencies [2][4] - Recent CDC data indicates a 27% decrease in drug overdose deaths in 2024, with opioid-related deaths dropping by 34%, although a subsequent increase in overdose deaths was reported, highlighting the ongoing need for effective response tools [3][4] Company Developments - Emergent acquired exclusive commercial rights to KLOXXADO Nasal Spray in January 2025, aiming to increase the availability of naloxone in the U.S. and Canada [2] - The company is also introducing Convenience Kits through NARCANDirect, which will include essential components for overdose response, such as a CPR mask and examination gloves [4] - Emergent emphasizes the importance of collaboration with various sectors to enhance community preparedness for opioid emergencies [4] Industry Context - The opioid crisis remains a significant public health challenge, necessitating continuous innovation and support in overdose response strategies [3][4] - The introduction of KLOXXADO Nasal Spray is part of a broader effort to combat the evolving nature of the opioid epidemic and improve emergency preparedness [3][4]

Fitch Ratings affirms BBB- long-term issuer rating with a stable outlookDALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest,” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, today announced that Fitch Ratings (“Fitch”) has affirmed Capital Southwest’s investment grade long-term issuer rating of BBB- with a stable out ...